Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporatio ...

Vancouver, BC, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X45) ("Deep Sea Minerals" or the "Company"), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce that the Company’s application to the U.S. Defense Industrial Base Consortium (the “DIBC”) has been approved.The DIBC is managed by Advanced Technology International (“ATI”) on behalf of the U.S. Department of Wa ...

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today annou ...

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce the completion of an extension to its previous ground gravity survey along the Coyote Corridor, located within the Southwestern Athabasca Basin Joint Venture (“JV”) Project in partnership with Atha Energy Corp. (TSX-V: SASK). The recently completed program represents a direct extension of the Company’s original gravity grid and was d ...

– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniks ...

DANBURY, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) -- announced the upcoming release of its first quarter 2026 results prior to the Stock Market Open on Monday, March 9, 2026. FuelCell Energy management will subsequently host a conference call with investors beginning at 10:00 a.m. Eastern Time the same day to discuss the results and provide a business update. Participants can access the live call via webcast on the Company website or by telephone as follows: The live web ...

Core Viewpoint - PTL Limited has announced the approval of a 1-for-80 share consolidation of its Class A and Class B ordinary shares to regain compliance with Nasdaq listing requirements [1][2]. Share Consolidation Details - The share consolidation will take effect on February 27, 2026, with Class A Ordinary Shares trading under the same symbol "PTLE" but with a new CUSIP number G7377S127 [2]. - Currently, there are 491,237,500 Class A Ordinary Shares and 11,250,000 Class B Ordinary Shares outstanding. Post-consolidation, there will be 6,140,469 Class A Ordinary Shares and 140,625 Class B Ordinary Shares outstanding [3]. - The consolidation will not result in fractional shares; any fractions will be rounded up to the next whole number [3]. Company Overview - PTL Limited is headquartered in Hong Kong and operates as a bunkering facilitator, providing marine fuel logistics services primarily for container ships, bulk carriers, general cargo vessels, and chemical tankers [4]. - The company targets the Asia Pacific market and leverages its established network within the marine fuel logistics industry to offer a one-stop solution for vessel refueling [4].

Core Viewpoint - Allied Properties Real Estate Investment Trust has received approval for a normal course issuer bid to repurchase up to 18,215,302 units, representing approximately 10% of its public float, primarily to fulfill employee commitments and potentially for cancellation [1][2]. Group 1: Normal Course Issuer Bid (NCIB) Details - The NCIB will commence on February 26, 2026, and will expire on February 25, 2027, or earlier if purchases are completed [2]. - Purchases will be made on the open market at prevailing market prices, with a daily limit of 213,464 units, which is 25% of the average daily trading volume over the past six months [2]. - The previous NCIB, which started on February 26, 2025, allowed for the purchase of up to 12,615,599 units, with 1,062 units repurchased at a weighted average price of $16.86 [3]. Group 2: Employee Programs and Repurchase Plans - The primary purpose of the NCIB is to fulfill commitments under Allied's restricted unit plan and other employee programs [1]. - Allied may enter into pre-defined plans with its broker to repurchase units during internal trading blackout periods, adhering to Canadian securities laws [4]. Group 3: Company Overview - Allied is a leading owner-operator of distinctive urban workspace in major Canadian cities, focusing on sustainable and wellness-oriented environments for knowledge-based organizations [6].

Core Insights - Quantum Transportation has successfully implemented its transformer-based neural decoder on the AWS cloud, marking a significant milestone for real-world quantum applications in the transportation sector [1][2] - The cloud deployment provides scalable infrastructure for processing complex quantum data efficiently, enhancing the potential for collaboration with quantum hardware design partners [2][3] - The technology aims to address error correction challenges in noisy quantum devices, with long-term applications in railway anomaly detection, predictive maintenance, and autonomous operations [3] Company Developments - Rail Vision Ltd. has acquired a 51% stake in Quantum Transportation, enhancing its focus on integrating quantum-AI innovations into the transportation sector [4] - Quantum Transportation is developing a Quantum Error Correction Simulator powered by a patented Transformer-based Universal Decoder, which aims to outperform classical decoders in accuracy and speed [5] - The patented Deep Quantum Error Correction Transformer introduces a novel machine-learning decoder that optimizes error correction across various quantum codes [5] Industry Impact - Rail Vision's technology is designed to transform railway safety and efficiency, potentially advancing the concept of autonomous trains into practical reality [6] - The integration of quantum error correction with AI-driven vision systems is expected to enhance safety and operational efficiency in railway operations [4][6]

Core Insights - Novartis announced new real-world studies on Pluvicto™ for metastatic prostate cancer, utilizing data from the PRECISION platform, to be presented at the ASCO Genitourinary Cancers Symposium [1] Group 1: Efficacy of Pluvicto - Pluvicto demonstrated a median progression-free survival (PFS) of 13.5 months in taxane-naïve mCRPC patients who had received at least one ARPI, with longer PFS observed in those treated after one ARPI (15.8 months) compared to multiple ARPIs (12.7 months) [2][3] - The findings align with the PSMAfore trial, which showed that Pluvicto more than doubled median rPFS compared to a change in ARPI (11.6 months vs. 5.6 months) [3] Group 2: Subsequent Therapies - A study indicated that mCRPC patients achieved meaningful clinical responses with systemic therapies after discontinuing Pluvicto, with median PFS of 8.6 months for all subsequent therapies [5][6] - Patients receiving ARPI after Pluvicto had a median PFS of 10.7 months, while those receiving taxane had a median PFS of 7.2 months [6] Group 3: Treatment Patterns and Guidelines - Real-world evidence showed significant gaps in guideline adherence for metastatic hormone-sensitive prostate cancer (mHSPC), with 39.2% of men receiving ADT monotherapy instead of the recommended combination therapy [8] - The data highlights an opportunity for improved patient care through adherence to clinical guidelines [8] Group 4: PRECISION Data Platform - The PRECISION platform harmonizes data from over 56,500 patients with metastatic prostate cancer to generate real-world evidence studies that inform clinical decisions [9]